Market Size of Digital Neurotherapeutics Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 362.63 Million |
| Market Size (2029) | USD 883.69 Million |
| CAGR (2024 - 2029) | 19.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Digital Neurotherapeutics Market Analysis
The Digital Neurotherapeutics Market size is estimated at USD 362.63 million in 2024, and is expected to reach USD 883.69 million by 2029, growing at a CAGR of 19.5% during the forecast period (2024-2029).
The major factors driving the digital neurotherapeutics market are the rising prevalence of neurological diseases and the growing adoption of digital technology in neurological care.
The rising prevalence of neurological diseases is expected to increase the demand for digital neurotherapeutics. For instance, as per the data by Alzheimer Europe in January 2023, Alzheimer's disease is the most prevalent neurodegenerative disease that affects 10 million individuals in Europe and is characterized by progressive, incapacitating memory loss and cognitive deficiencies brought on by a buildup of harmful proteins in the brain. Hence, the increasing demand for non-invasive digital neurotherapeutics treatment for this health condition may drive market growth over the forecast period.
The rising prevalence of Parkinson’s disease is also expected to drive the growth of the market over the forecast period. Digital therapeutics, i.e., treatments delivered remotely and enabled by modern technology, facilitate the provision of personalized, evidence-based, interdisciplinary interventions to manage the complexities associated with Parkinson's disease. As per the 2022 update from the Parkinson’s Foundation, nearly one million people in the United States are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Hence, the rising prevalence of Parkinson’s disease is expected to drive the growth of the market over the forecast period.
Furthermore, the growing adoption of digital neurotherapeutics in the treatment of various neurological diseases is also expected to boost market growth. For instance, in February 2023, MindMaze, an AI-driven digital neurotherapeutics company, launched its Izar device in the United States and Europe. This device has applications in the treatment of stroke, Parkinson’s disease, Alzheimer’s disease, and traumatic brain injury (TBI). Hence, the launch of such devices increases the demand for accessibility and adoption of digital neurotherapeutics.
Thus, the rising prevalence of neurological diseases and the growing adoption of digital neurotherapeutics in the treatment of various neurological diseases are expected to drive the growth of the market studied over the forecast period. However, stringent regulatory requirements are expected to restrain the market growth over the forecast period.
